Cargando…
Loading, please waitCargando…
Loading, please waitCondition Focus — Peripheral Neuropathy
A clear, conservative explanation of where mesenchymal stem cell (MSC) therapy stands for peripheral neuropathy in 2026 — at Regeneris Therapy, a COFEPRIS-regulated regenerative-medicine clinic in Cancún, México. What the published evidence actually shows, who may be a reasonable candidate, what an MSC adjunct can and cannot promise, and how an honest physician-led evaluation works.
Clinical overview
Peripheral neuropathy is a broad term for damage to the nerves outside the brain and spinal cord — the sensory, motor, and autonomic fibers that connect the central nervous system with the limbs and organs. It is a symptom of an underlying process rather than a single disease, and accurate diagnosis (cause, distribution, severity) is the foundation of any honest treatment plan. Standard care is driven by the underlying cause: tight glycemic control in diabetes, modifying or pausing offending chemotherapy, immunomodulation in inflammatory neuropathies, vitamin repletion in deficiency states, plus symptomatic pharmacology and physical therapy. Regenerative medicine sits alongside that standard, not in place of it.
MSC therapy is studied as an adjunct that may modulate the inflammatory and metabolic environment that drives nerve injury — not as a stand-alone substitute for the cause-directed and symptomatic care your physician has prescribed. Any conversation about it in Cancún, México starts from that premise.
What the evidence shows
An honest summary of the published evidence for mesenchymal stem cell therapy in peripheral neuropathy. The signal is real but modest: small controlled human trials and a recent systematic review report safety and statistically significant gains in nerve conduction and symptom scores for diabetic peripheral neuropathy, but these are not approval-grade efficacy trials. For chemotherapy-induced and other neuropathies, the human evidence is earlier still and primarily preclinical. None of this guarantees an individual outcome, and a Regeneris physician matches the modality to the strength of evidence for your specific case in Cancún, México.
The field's own founder reframed these cells as "medicinal signaling cells," arguing that their benefit comes chiefly from secreted, paracrine factors (exosomes, cytokines, growth factors) that modulate inflammation, recruit local progenitors, and restore a healthier microenvironment — not from engraftment and tissue replacement. This is the mechanistic basis on which MSC protocols for nerve-injury and metabolic neuropathies are studied.
A 2024 systematic review and meta-analysis pooled seven human controlled trials of stem cell transplantation for diabetic peripheral neuropathy (bone-marrow mononuclear cells and umbilical-cord MSCs, mostly intramuscular). The pooled estimates showed small but statistically significant improvements in motor and sensory nerve conduction velocity and in clinical symptom scores (Toronto Clinical Scoring System, vibration perception threshold). Adverse events were limited to mild, transient injection-site pain and swelling. The authors conclude the signal is "significant promise" but underline that larger, well-designed trials are still needed before clinical adoption.
A 2024 systematic review and meta-analysis of 23 preclinical (animal) studies of MSC therapy for diabetic neuropathy reported improvements in motor and sensory nerve conduction velocity, intra-epidermal nerve fiber (IENF) density, and sciatic nerve blood flow, paired with increased neurotrophic and angiogenic factors and reduced inflammatory cytokines. The authors frame these findings as mechanistic support — and call for well-designed clinical trials to confirm them in patients.
An early preclinical study tested specially prepared anti-inflammatory MSCs ("MSC2") in a mouse model of painful diabetic peripheral neuropathy. MSC2-treated animals showed restoration of mechanical and thermal pain responses toward healthy-mouse levels and a measurable decrease in serum pro-inflammatory cytokines, supporting an immune-modulatory mechanism for the analgesic effect. The authors position this as hypothesis-generating evidence for a new anti-inflammatory approach in painful neuropathy — not as established human therapy.
A 2020 review surveyed the rationale and early evidence for MSC therapy in chemotherapy-induced peripheral neuropathy (CIPN), framing it as a biologically plausible but still investigational approach. MSCs are described as reducing oxidative stress, neuroinflammation, and apoptosis and supporting axonal regeneration in preclinical models, but the authors emphasize that the approach "requires further investigations" before clinical recommendations can be made.
The honest takeaway: MSC therapy for peripheral neuropathy shows a biologically plausible mechanism, a consistent safety profile in small trials, and a modest but real signal in diabetic peripheral neuropathy — but it is not an approved therapy and we will not promise nerve regrowth, pain resolution, or cure. We will tell you that during your evaluation in Cancún, México.
Honest candidacy
MSC therapy for peripheral neuropathy is considered only as a careful adjunct, after coordinating with your treating physician and confirming the underlying cause. The bullets below are general orientation — not a substitute for an evaluation in Cancún, México.
Regulation & location
Regeneris Therapy is a regenerative-medicine clinic in Cancún, México, regulated by COFEPRIS — Mexico's federal health authority, equivalent in scope to the U.S. FDA. Operating in Cancún means three things at once: a federally regulated medical environment, a recognized international medical-tourism destination on the Mexican Caribbean with direct flights from across the U.S. and Canada, and a single coordinated team for evaluation, treatment, and follow-up — particularly valuable for patients traveling for a multi-day neuropathy assessment.
Regeneris operates under Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053 — registered medical activity under Mexican federal regulation, performed in Cancún, México.
Cells are sourced, processed, and stored through COFEPRIS-certified laboratory partners with documented sterility, viability, and identity testing for every batch — the same supply chain used across our stem-cell protocols in Cancún, México.
Every peripheral neuropathy case is reviewed by a licensed physician in Cancún, México. Your neurology, endocrinology, oncology, or primary-care notes — plus recent nerve conduction studies, A1c or relevant labs, and current medications — are part of the conversation. Coordination, not replacement, is the rule.
How Regeneris works
Our model is simple and deliberate: a free medical evaluation first, a personalized written quote second, and a decision that is yours to make in your own time. We do not publish prices online for regenerative protocols and we do not bundle peripheral neuropathy into an off-the-shelf package — every case is individualized in Cancún, México.
Send your diagnosis (underlying cause and duration), current medications, recent A1c or relevant labs, nerve conduction or EMG results when available, and any specialist notes. A Regeneris physician in Cancún, México reviews your case and decides honestly whether MSC therapy is a reasonable adjunct, deferred, or not appropriate.
If MSC therapy is reasonable, your physician designs a plan that respects your existing neurology, endocrinology, and pain-management care — never replaces it — and explains realistic expectations, including that this is investigational for peripheral neuropathy.
Only after the evaluation do you receive a personalized written quote with the proposed protocol, scope, and inclusions. There are no online prices because there is no standard package — your cause, severity, and goals dictate the plan.
If you proceed, your visit to Cancún, México is coordinated end-to-end — evaluation, infusion under medical supervision, and structured follow-up with your home specialists looped in for ongoing cause-directed care.
Realistic expectations
Peripheral neuropathy is a YMYL (your-money-or-your-life) topic and we treat it that way. We will not promise nerve regrowth, full pain resolution, or replacement of your standard neurology and metabolic care. We will explain what is known, what is not, and what an adjunct can reasonably aim for under conservative medical supervision in Cancún, México.
It is not an approved treatment. The largest pooled human dataset to date (Alizadeh 2024, seven controlled trials) reported small but significant signals in diabetic PN — not approval-grade efficacy. Any individual response is uncertain.
MSC therapy at Regeneris is studied and discussed only as an adjunct to your treating physician's plan — never as a reason to stop glycemic management, immunotherapy, chemotherapy adjustments, or symptomatic pharmacology without your specialist's decision.
We do not publish prices online and do not sell a single peripheral neuropathy package. Every plan and quote is individualized after a free medical evaluation.
We will not market MSC therapy as a nerve-regeneration cure, pain elimination, or guaranteed return of function. Where the evidence is uncertain we will say so, in your written plan and in conversation.
FAQ
The questions patients with peripheral neuropathy most often ask us before traveling to Cancún, México for an evaluation.
No. There is no proven cure for peripheral neuropathy with stem cells. Mesenchymal stem cell (MSC) therapy for peripheral neuropathy is investigational, not an approved treatment. The largest pooled human dataset to date — a 2024 systematic review and meta-analysis of seven controlled trials in diabetic peripheral neuropathy (Alizadeh et al., Stem Cell Research & Therapy) — reported small but statistically significant gains in nerve conduction velocity and symptom scores, with a benign safety profile. That is encouraging, but it is not approval-grade efficacy and it does not guarantee nerve regrowth, pain resolution, or cure for any individual patient. At Regeneris Therapy in Cancún, México we offer MSC therapy only as a careful adjunct to your existing neurology, endocrinology, and pain-management care — never as a substitute and never as a cure.
The published human evidence is most developed in diabetic peripheral neuropathy. The 2024 meta-analysis pooled seven controlled trials of bone-marrow mononuclear cells and umbilical-cord MSCs (mostly intramuscular) and reported statistically significant improvements in motor and sensory nerve conduction velocity, vibration perception threshold, and the Toronto Clinical Scoring System, with adverse events limited to mild, transient injection-site pain and swelling. The authors describe the signal as "significant promise" but emphasize that larger, well-designed trials are still needed before clinical adoption. In plain English: real signal, small sample, investigational status. At Regeneris in Cancún, México we offer MSC therapy for diabetic PN only as an adjunct, alongside glycemic and metabolic control directed by your endocrinologist or primary-care physician.
The human evidence for MSC therapy in chemotherapy-induced peripheral neuropathy is earlier and predominantly preclinical. A 2020 review (Al-Massri et al., J Tissue Eng Regen Med) describes MSC therapy as biologically plausible — reducing oxidative stress, neuroinflammation, and apoptosis while supporting axonal regeneration in animal models — but explicitly states the approach "requires further investigations" before clinical recommendations. At Regeneris Therapy in Cancún, México we will discuss CIPN candidacy with you only as an investigational adjunct, with your oncologist informed, and with honest framing that the human evidence is early.
No — and any clinic that suggests so should be treated with extreme caution. Symptomatic medication (gabapentin, pregabalin, duloxetine, topical agents, tricyclics), glycemic and metabolic management in diabetes, immunotherapy for inflammatory neuropathies, and chemotherapy-related adjustments are decisions for your treating physician. MSC therapy at Regeneris Therapy in Cancún, México is discussed only as an adjunct, with your physicians informed, and never as a reason to discontinue cause-directed or symptomatic care. Any change to your medication or to your underlying-disease management is a decision for your treating specialist, not for a regenerative-medicine clinic.
In general terms, adults with a confirmed peripheral neuropathy diagnosis, an identified underlying cause, and standard care already in place — for example, diabetic PN patients with reasonable glycemic control under endocrinology, or chemotherapy-induced PN patients whose oncologist is supportive of an investigational adjunct. Patients with active untreated malignancy, uncontrolled infection, uncontrolled diabetes, severe immunosuppression without specialist coordination, pregnancy or lactation, or those seeking a single-procedure cure are not candidates here. Final candidacy is always confirmed in a free medical evaluation in Cancún, México — not assumed from a symptom or diagnosis alone.
You start with a free medical evaluation — send your diagnosis, the underlying cause and duration, current medications, recent A1c or relevant labs, nerve conduction or EMG results when available, and any specialist notes through our contact form or WhatsApp. A Regeneris physician in Cancún, México reviews your case and either proposes a coordinated plan or honestly declines. We do not publish prices online for regenerative protocols and we do not sell an off-the-shelf peripheral neuropathy package; any personalized written quote is issued only after the evaluation, so the figure you see reflects your specific case — cause, severity, and goals — rather than a generic list.
Continue exploring
The full pillar on mesenchymal stem cell therapy at Regeneris in Cancún, México: cell sources, mechanism, protocols, and how to start.
ContinueHow COFEPRIS regulation, certified labs, and physician oversight make stem-cell care in Cancún, México different from unregulated tourism.
ContinueTravel, logistics, and what to bring from your neurologist or endocrinologist when coming to Cancún, México from the U.S. or Canada.
ContinueA 2026 comparison of regulation, available cell types, and cross-border considerations for regenerative care in Cancún, México.
ContinueSend your peripheral neuropathy diagnosis, cause, current medications, and recent labs to start a free medical evaluation in Cancún, México.
ContinueThis page is informational and does not constitute medical advice. Mesenchymal stem cell therapy is investigational for peripheral neuropathy and is not an approved treatment; outcomes are uncertain and vary by patient, underlying cause, severity, and protocol. MSC therapy is not a cure for peripheral neuropathy and is offered at Regeneris Therapy in Cancún, México only as an adjunct to cause-directed care prescribed by your treating physicians, after a free medical evaluation. Regeneris Therapy operates under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053 in Cancún, Quintana Roo, México.
Book a free 15-min call with our team.
Share your diagnosis, the underlying cause, current medications, recent A1c or labs, and nerve conduction studies if available. A physician in Cancún, México will review your case and tell you honestly whether an MSC adjunct is reasonable, deferred, or not appropriate — with a personalized written quote after your free medical evaluation.